Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the earnings per share (EPS) high or low?
The earnings per share (EPS) of -9.75 is 83% above its 5-year average of -56.40, near the high end of its 5-year range (-173.87–-2.52).
73.88% above its 12-month average of -37.33.
Reported quarterly EPS; no daily interpolation. Q2 FY2026 (2026-06-30): -2.56.
EPS growth vs the same fiscal quarter in the prior fiscal year, last 9 comparable quarters.
EARNINGS PER SHARE (EPS)
-9.75
EARNINGS PER SHARE (EPS) AVG TTM
-37.33
EARNINGS PER SHARE (EPS) AVG 3Y
-73.93
EARNINGS PER SHARE (EPS) AVG 5Y
-56.40
EARNINGS PER SHARE (EPS) AVG 10Y
N/A
EARNINGS PER SHARE (EPS) AVG 15Y
N/A
EARNINGS PER SHARE (EPS) AVG 20Y
N/A
CURRENT VS TTM AVG
+73.88%
CURRENT VS 3Y AVG
+86.81%
CURRENT VS 5Y AVG
+82.71%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
GRAIL Inc.
Market Cap
$6.02B
Earnings Per Share (EPS)
-9.75
TTM Avg
-37.33
3Y Avg
-73.93
5Y Avg
-56.40
Market Cap
$5.92B
Earnings Per Share (EPS)
9.35
TTM Avg
3.11
3Y Avg
1.82
5Y Avg
1.76
Market Cap
$5.90B
Earnings Per Share (EPS)
-0.70
TTM Avg
-1.19
3Y Avg
-1.69
5Y Avg
-1.81
Market Cap
$6.25B
Earnings Per Share (EPS)
-3.11
TTM Avg
-3.72
3Y Avg
-3.54
5Y Avg
-3.08
Market Cap
$5.74B
Earnings Per Share (EPS)
0.98
TTM Avg
0.10
3Y Avg
0.76
5Y Avg
-0.31
Market Cap
$5.67B
Earnings Per Share (EPS)
-2.70
TTM Avg
-1.75
3Y Avg
-1.29
5Y Avg
-1.09
Market Cap
$6.49B
Earnings Per Share (EPS)
0.49
TTM Avg
-0.07
3Y Avg
-0.37
5Y Avg
-0.14
Market Cap
$6.50B
Earnings Per Share (EPS)
4.14
TTM Avg
3.99
3Y Avg
3.29
5Y Avg
1.98
Market Cap
$5.54B
Earnings Per Share (EPS)
-0.27
TTM Avg
-0.11
3Y Avg
0.01
5Y Avg
0.03
| NAME | MARKET CAP | EARNINGS PER SHARE (EPS) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| GRAIL Inc. (GRAL) | $6.02B | -9.75 | -37.33 | -73.93 | -56.40 |
| Ligand Pharmaceuticals Incorporated (LGND)vs › | $5.92B | 9.35 | 3.11 | 1.82 | 1.76 |
| Iovance Biotherapeutics, Inc. (IOVA)vs › | $5.90B | -0.70 | -1.19 | -1.69 | -1.81 |
| Rhythm Pharmaceuticals, Inc. (RYTM)vs › | $6.25B | -3.11 | -3.72 | -3.54 | -3.08 |
| Kiniksa Pharmaceuticals International, plc (KNSA)vs › | $5.74B | 0.98 | 0.10 | 0.76 | -0.31 |
| CG Oncology Inc. (CGON)vs › | $5.67B | -2.70 | -1.75 | -1.29 | -1.09 |
| Amneal Pharmaceuticals, Inc. (AMRX)vs › | $6.49B | 0.49 | -0.07 | -0.37 | -0.14 |
| Lantheus Holdings, Inc. (LNTH)vs › | $6.50B | 4.14 | 3.99 | 3.29 | 1.98 |
| RadNet, Inc. (RDNT)vs › | $5.54B | -0.27 | -0.11 | 0.01 | 0.03 |
| MiniMed Group, Inc. Common Stock (MMED)vs › | $5.53B | -1.10 | -1.09 | -0.73 | -0.73 |
Trailing EPS (TTM)
$-9.75
Forward EPS (Est.)
$-9.62
P/E Ratio
N/A
Formula: EPS = Net Income / Weighted Average Shares Outstanding
Why EPS matters:
EPS (Earnings Per Share) represents the portion of a company's profit allocated to each outstanding share. Higher EPS indicates greater profitability on a per-share basis.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EARNINGS PER SHARE (EPS) |
|---|---|
| 2025-12-31 | -11.11 |
| 2024-12-31 | -63.54 |
| 2023-12-31 | -47.20 |
| 2022-12-31 | -173.87 |
| 2021-12-31 | -40.18 |
| 2020-12-31 | -2.52 |
| 2019-12-31 | -1.99 |
| 2018-12-31 | -2.42 |
